CASI Pharmaceuticals, Inc. (CASI)
USD 2.07
(-2.59%)
USD 2.07
(-2.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 51.1 Million USD | 74.4% |
| 2022 | 29.3 Million USD | -3.42% |
| 2021 | 30.33 Million USD | 25.57% |
| 2020 | 24.16 Million USD | 169.47% |
| 2019 | 8.96 Million USD | 127.13% |
| 2018 | 3.94 Million USD | -39.83% |
| 2017 | 6.56 Million USD | -5.31% |
| 2016 | 6.92 Million USD | -41.84% |
| 2015 | 11.91 Million USD | 1.55% |
| 2014 | 11.73 Million USD | 1975.81% |
| 2013 | 565.16 Thousand USD | -23.91% |
| 2012 | 742.75 Thousand USD | 5.49% |
| 2011 | 704.09 Thousand USD | -73.96% |
| 2010 | 2.7 Million USD | -77.46% |
| 2009 | 11.99 Million USD | -47.86% |
| 2008 | 23 Million USD | -11.93% |
| 2007 | 26.11 Million USD | 198.88% |
| 2006 | 8.73 Million USD | 24.03% |
| 2005 | 7.04 Million USD | 91.34% |
| 2004 | 3.68 Million USD | -30.23% |
| 2003 | 5.27 Million USD | -69.49% |
| 2002 | 17.29 Million USD | -24.81% |
| 2001 | 23 Million USD | 86.24% |
| 2000 | 12.35 Million USD | 26.05% |
| 1999 | 9.8 Million USD | 53.13% |
| 1998 | 6.4 Million USD | 12.28% |
| 1997 | 5.7 Million USD | -10.94% |
| 1996 | 6.4 Million USD | -1.54% |
| 1995 | 6.5 Million USD | 983.33% |
| 1994 | 600 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 42.25 Million USD | -0.69% |
| 2024 Q1 | 42.54 Million USD | -16.75% |
| 2023 Q1 | 26.17 Million USD | -10.68% |
| 2023 Q3 | 23.79 Million USD | -0.99% |
| 2023 FY | 51.1 Million USD | 74.4% |
| 2023 Q2 | 24.03 Million USD | -8.18% |
| 2023 Q4 | 51.1 Million USD | 114.77% |
| 2022 Q1 | 30.84 Million USD | 1.68% |
| 2022 Q3 | 44.69 Million USD | 52.78% |
| 2022 Q4 | 29.3 Million USD | -34.44% |
| 2022 Q2 | 29.25 Million USD | -5.17% |
| 2022 FY | 29.3 Million USD | -3.42% |
| 2021 FY | 30.33 Million USD | 25.57% |
| 2021 Q2 | 27.02 Million USD | 4.37% |
| 2021 Q3 | 26.76 Million USD | -1.0% |
| 2021 Q4 | 30.33 Million USD | 13.37% |
| 2021 Q1 | 25.89 Million USD | 7.19% |
| 2020 Q4 | 24.16 Million USD | 12.69% |
| 2020 Q1 | 8.24 Million USD | -8.04% |
| 2020 Q2 | 7.15 Million USD | -13.21% |
| 2020 Q3 | 21.44 Million USD | 199.61% |
| 2020 FY | 24.16 Million USD | 169.47% |
| 2019 Q3 | 8.24 Million USD | 5.43% |
| 2019 Q4 | 8.96 Million USD | 8.81% |
| 2019 Q1 | 6.84 Million USD | 73.45% |
| 2019 FY | 8.96 Million USD | 127.13% |
| 2019 Q2 | 7.81 Million USD | 14.15% |
| 2018 Q1 | 3.54 Million USD | -46.0% |
| 2018 Q3 | 6.98 Million USD | 66.81% |
| 2018 Q2 | 4.18 Million USD | 18.23% |
| 2018 Q4 | 3.94 Million USD | -43.51% |
| 2018 FY | 3.94 Million USD | -39.83% |
| 2017 Q2 | 7.1 Million USD | 2.38% |
| 2017 FY | 6.56 Million USD | -5.31% |
| 2017 Q4 | 6.56 Million USD | -8.09% |
| 2017 Q3 | 7.13 Million USD | 0.44% |
| 2017 Q1 | 6.94 Million USD | 0.19% |
| 2016 FY | 6.92 Million USD | -41.84% |
| 2016 Q4 | 6.92 Million USD | -20.66% |
| 2016 Q2 | 8.94 Million USD | -9.55% |
| 2016 Q3 | 8.73 Million USD | -2.35% |
| 2016 Q1 | 9.88 Million USD | -17.0% |
| 2015 Q3 | 11.83 Million USD | -1.6% |
| 2015 FY | 11.91 Million USD | 1.55% |
| 2015 Q4 | 11.91 Million USD | 0.67% |
| 2015 Q1 | 12.01 Million USD | 2.39% |
| 2015 Q2 | 12.02 Million USD | 0.12% |
| 2014 Q2 | 743.35 Thousand USD | -1.66% |
| 2014 Q4 | 11.73 Million USD | 1.38% |
| 2014 Q3 | 11.57 Million USD | 1456.82% |
| 2014 FY | 11.73 Million USD | 1975.81% |
| 2014 Q1 | 755.92 Thousand USD | 33.75% |
| 2013 FY | 565.16 Thousand USD | -23.91% |
| 2013 Q4 | 565.16 Thousand USD | 12.72% |
| 2013 Q3 | 501.4 Thousand USD | -33.12% |
| 2013 Q2 | 749.73 Thousand USD | -5.64% |
| 2013 Q1 | 794.57 Thousand USD | 6.98% |
| 2012 Q4 | 742.75 Thousand USD | 2.29% |
| 2012 Q2 | 944.81 Thousand USD | -90.14% |
| 2012 Q1 | 9.58 Million USD | 1260.94% |
| 2012 FY | 742.75 Thousand USD | 5.49% |
| 2012 Q3 | 726.14 Thousand USD | -23.14% |
| 2011 FY | 704.09 Thousand USD | -73.96% |
| 2011 Q3 | 760.29 Thousand USD | -40.65% |
| 2011 Q1 | 1.71 Million USD | -36.68% |
| 2011 Q2 | 1.28 Million USD | -25.17% |
| 2011 Q4 | 704.09 Thousand USD | -7.39% |
| 2010 Q1 | 9.2 Million USD | -23.26% |
| 2010 FY | 2.7 Million USD | -77.46% |
| 2010 Q4 | 2.7 Million USD | -41.37% |
| 2010 Q3 | 4.61 Million USD | -31.45% |
| 2010 Q2 | 6.72 Million USD | -26.9% |
| 2009 Q4 | 11.99 Million USD | -15.25% |
| 2009 FY | 11.99 Million USD | -47.86% |
| 2009 Q1 | 18.85 Million USD | -18.02% |
| 2009 Q2 | 16.07 Million USD | -14.74% |
| 2009 Q3 | 14.15 Million USD | -11.98% |
| 2008 Q1 | 25.98 Million USD | -0.49% |
| 2008 FY | 23 Million USD | -11.93% |
| 2008 Q3 | 24.3 Million USD | -5.87% |
| 2008 Q2 | 25.82 Million USD | -0.65% |
| 2008 Q4 | 23 Million USD | -5.36% |
| 2007 Q4 | 26.11 Million USD | 0.48% |
| 2007 Q1 | 7.72 Million USD | -11.64% |
| 2007 Q3 | 25.99 Million USD | 268.18% |
| 2007 FY | 26.11 Million USD | 198.88% |
| 2007 Q2 | 7.05 Million USD | -8.57% |
| 2006 Q2 | 6.95 Million USD | 3.55% |
| 2006 FY | 8.73 Million USD | 24.03% |
| 2006 Q4 | 8.73 Million USD | 14.37% |
| 2006 Q3 | 7.64 Million USD | 9.93% |
| 2006 Q1 | 6.71 Million USD | -4.73% |
| 2005 Q1 | 5.09 Million USD | 38.25% |
| 2005 FY | 7.04 Million USD | 91.34% |
| 2005 Q4 | 7.04 Million USD | 52.87% |
| 2005 Q3 | 4.6 Million USD | 45.29% |
| 2005 Q2 | 3.17 Million USD | -37.69% |
| 2004 FY | 3.68 Million USD | -30.23% |
| 2004 Q3 | 2.54 Million USD | -4.82% |
| 2004 Q1 | 3.19 Million USD | -39.45% |
| 2004 Q2 | 2.67 Million USD | -16.19% |
| 2004 Q4 | 3.68 Million USD | 44.44% |
| 2003 Q2 | 3.05 Million USD | -49.92% |
| 2003 Q4 | 5.27 Million USD | 68.43% |
| 2003 Q3 | 3.13 Million USD | 2.61% |
| 2003 FY | 5.27 Million USD | -69.49% |
| 2003 Q1 | 6.09 Million USD | -64.75% |
| 2002 Q1 | 16.86 Million USD | -26.68% |
| 2002 Q2 | 13.24 Million USD | -21.49% |
| 2002 FY | 17.29 Million USD | -24.81% |
| 2002 Q3 | 18.04 Million USD | 36.25% |
| 2002 Q4 | 17.29 Million USD | -4.13% |
| 2001 Q3 | 20.26 Million USD | 28.57% |
| 2001 Q1 | 13.94 Million USD | 12.88% |
| 2001 FY | 23 Million USD | 86.24% |
| 2001 Q4 | 23 Million USD | 13.54% |
| 2001 Q2 | 15.76 Million USD | 13.03% |
| 2000 Q1 | 7.27 Million USD | -25.76% |
| 2000 FY | 12.35 Million USD | 26.05% |
| 2000 Q3 | 8.54 Million USD | -3.45% |
| 2000 Q4 | 12.35 Million USD | 44.53% |
| 2000 Q2 | 8.85 Million USD | 21.67% |
| 1999 Q3 | 5.3 Million USD | -13.11% |
| 1999 Q4 | 9.8 Million USD | 84.91% |
| 1999 Q2 | 6.1 Million USD | -4.69% |
| 1999 Q1 | 6.4 Million USD | 0.0% |
| 1999 FY | 9.8 Million USD | 53.13% |
| 1998 Q4 | 6.4 Million USD | 42.22% |
| 1998 FY | 6.4 Million USD | 12.28% |
| 1998 Q1 | 4.7 Million USD | -17.54% |
| 1998 Q2 | 5.1 Million USD | 8.51% |
| 1998 Q3 | 4.5 Million USD | -11.76% |
| 1997 Q1 | 5.4 Million USD | -15.63% |
| 1997 Q2 | 5.7 Million USD | 5.56% |
| 1997 FY | 5.7 Million USD | -10.94% |
| 1997 Q3 | 4.2 Million USD | -26.32% |
| 1997 Q4 | 5.7 Million USD | 35.71% |
| 1996 Q4 | 6.4 Million USD | 8.47% |
| 1996 Q1 | 6.5 Million USD | 0.0% |
| 1996 FY | 6.4 Million USD | -1.54% |
| 1996 Q3 | 5.9 Million USD | -9.23% |
| 1996 Q2 | 6.5 Million USD | 0.0% |
| 1995 FY | 6.5 Million USD | 983.33% |
| 1995 Q4 | 6.5 Million USD | 0.0% |
| 1994 FY | 600 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 84.781% |
| Alkermes plc | 933.53 Million USD | 94.526% |
| Agenus Inc. | 462.29 Million USD | 88.946% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 98.738% |
| Aptorum Group Limited | 5.25 Million USD | -872.143% |
| Ardelyx, Inc. | 130.76 Million USD | 60.919% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 89.318% |
| Bicycle Therapeutics plc | 224.41 Million USD | 77.228% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 60.753% |
| ChromaDex Corporation | 26.5 Million USD | -92.783% |
| Chimerix, Inc. | 19.74 Million USD | -158.815% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -45.273% |
| Caribou Biosciences, Inc. | 72.56 Million USD | 29.578% |
| CRISPR Therapeutics AG | 346.76 Million USD | 85.263% |
| Precision BioSciences, Inc. | 140.92 Million USD | 63.736% |
| Dyadic International, Inc. | 2.34 Million USD | -2083.281% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -214.229% |
| Fortress Biotech, Inc. | 165.93 Million USD | 69.204% |
| Lantern Pharma Inc. | 2.73 Million USD | -1765.289% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | 28.507% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -1348.2% |
| Incyte Corporation | 1.59 Billion USD | 96.791% |
| IO Biotech, Inc. | 17.55 Million USD | -191.086% |
| Jaguar Health, Inc. | 45.86 Million USD | -11.418% |
| Novavax, Inc. | 2.57 Billion USD | 98.013% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -41.724% |
| Opthea Limited | 264.6 Million USD | 80.687% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 60.903% |
| ContextLogic Inc. | 206 Million USD | 75.193% |
| MiMedx Group, Inc. | 96.33 Million USD | 46.95% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -6.416% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -1348.134% |
| NextCure, Inc. | 14.99 Million USD | -240.755% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -1164.3% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -665.359% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -9.337% |
| Vaxcyte, Inc. | 167.44 Million USD | 69.481% |
| PDS Biotechnology Corporation | 33.25 Million USD | -53.651% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 78.274% |
| Pharming Group N.V. | 244.07 Million USD | 79.062% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -328.645% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 60.01% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -673.435% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -673.435% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 38.007% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -669.276% |
| Acelyrin, Inc. | 86.35 Million USD | 40.821% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -3833.296% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -255.4% |
| Summit Therapeutics Inc. | 125.25 Million USD | 59.201% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -439.118% |
| Senti Biosciences, Inc. | 52.57 Million USD | 2.792% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | 25.698% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 66.271% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -2512.628% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -3726.324% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 77.471% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -445.564% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 77.532% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 89.666% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -368.233% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -85.755% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -322.175% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 89.498% |
| Immix Biopharma, Inc. | 3.72 Million USD | -1273.078% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -35.15% |
| MEI Pharma, Inc. | 8.35 Million USD | -511.646% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -76.126% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 85.297% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 64.967% |
| Fortress Biotech, Inc. | 165.93 Million USD | 69.204% |
| Precigen, Inc. | 41.64 Million USD | -22.714% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -2.349% |
| AlloVir, Inc. | 45.01 Million USD | -13.524% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 60.792% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 62.915% |
| ImmuCell Corporation | 18.81 Million USD | -171.607% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -81.049% |
| Onconetix, Inc. | 23.18 Million USD | -120.453% |
| PureTech Health plc | 125.58 Million USD | 59.307% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -470.983% |
| Elevation Oncology, Inc. | 34.28 Million USD | -49.067% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -1990.102% |
| Seer, Inc. | 39.36 Million USD | -29.818% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | 17.355% |
| Innoviva, Inc. | 568.55 Million USD | 91.012% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -87.685% |
| ESSA Pharma Inc. | 3.49 Million USD | -1362.145% |
| GlycoMimetics, Inc. | 6.9 Million USD | -640.401% |
| GT Biopharma, Inc. | 6.63 Million USD | -670.436% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 80.671% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 81.232% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | 39.182% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -422.846% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -88.093% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -1484.209% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | 30.724% |
| Aptose Biosciences Inc. | 15.8 Million USD | -223.259% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -362.903% |
| Soligenix, Inc. | 7.27 Million USD | -602.456% |
| Century Therapeutics, Inc. | 175.94 Million USD | 70.954% |
| Kura Oncology, Inc. | 51.66 Million USD | 1.082% |
| TScan Therapeutics, Inc. | 121.28 Million USD | 57.864% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -1136.463% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -672.666% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 79.769% |
| Autolus Therapeutics plc | 263.9 Million USD | 80.636% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -387.531% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | 42.491% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -8.964% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 85.517% |
| GRI Bio, Inc. | 2.69 Million USD | -1794.809% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -6212.246% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -64.366% |
| IGM Biosciences, Inc. | 220.17 Million USD | 76.79% |
| INmune Bio, Inc. | 18.86 Million USD | -170.931% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 80.075% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -91.815% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -1779.888% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -1457.892% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | 12.577% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | 46.856% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 80.697% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 93.791% |
| Verastem, Inc. | 71.18 Million USD | 28.211% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -3.919% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -32.467% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -4.437% |
| Histogen Inc. | 5.69 Million USD | -797.016% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -1065.244% |
| Surrozen, Inc. | 8.14 Million USD | -527.416% |
| Organovo Holdings, Inc. | 2.74 Million USD | -1759.643% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -16182.204% |
| Ovid Therapeutics Inc. | 56.22 Million USD | 9.118% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -209.49% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -6080.257% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | 59.674% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -372.581% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 66.132% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -1859.963% |
| Apollomics, Inc. | 14.15 Million USD | -261.075% |
| Amarin Corporation plc | 279.58 Million USD | 81.722% |
| Mesoblast Limited | 188.79 Million USD | 72.932% |
| Turnstone Biologics Corp. | 14.14 Million USD | -261.203% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 71.733% |
| Synaptogenix, Inc. | 5.52 Million USD | -824.194% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -668.697% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 69.958% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -497.193% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -2807.887% |
| Exelixis, Inc. | 678.44 Million USD | 92.468% |
| Better Therapeutics, Inc. | 23.84 Million USD | -114.34% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 68.848% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 91.4% |
| NLS Pharmaceutics AG | 10.68 Million USD | -378.483% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -3047.481% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -31.279% |
| Gritstone bio, Inc. | 125.91 Million USD | 59.416% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -248.208% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -904.259% |
| Avid Bioservices, Inc. | 275.66 Million USD | 81.462% |
| Insmed Incorporated | 1.66 Billion USD | 96.925% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -564.191% |
| MediWound Ltd. | 27.18 Million USD | -87.969% |
| OmniAb, Inc. | 87.4 Million USD | 41.53% |
| Alector, Inc. | 487.66 Million USD | 89.521% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 87.334% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -177.357% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -33.174% |
| Zai Lab Limited | 240.17 Million USD | 78.723% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 91.889% |
| Aura Biosciences, Inc. | 29.22 Million USD | -74.849% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | 46.251% |
| Immunic, Inc. | 25.36 Million USD | -101.447% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | 26.19% |
| Veracyte, Inc. | 93.71 Million USD | 45.472% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -1852.976% |
| FibroGen, Inc. | 585.72 Million USD | 91.275% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -193.983% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -7724.97% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -803.605% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 99.333% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -523.359% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | 39.179% |
| TG Therapeutics, Inc. | 169.08 Million USD | 69.777% |
| Galecto, Inc. | 5.89 Million USD | -766.74% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -516.888% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 98.048% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -77.306% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -304.905% |
| XBiotech Inc. | 8.39 Million USD | -508.586% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -248.208% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | 3.906% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 85.926% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -90.087% |
| Theravance Biopharma, Inc. | 169 Million USD | 69.762% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 95.796% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 89.788% |
| Vaxxinity, Inc. | 30.94 Million USD | -65.147% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 94.745% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -747.324% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 93.143% |
| NexImmune, Inc. | 5.08 Million USD | -905.127% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -13659.781% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -1561.968% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.281% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -891.515% |
| Scopus BioPharma Inc. | 7.45 Million USD | -585.538% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -94.352% |
| Ainos, Inc. | 7.39 Million USD | -591.121% |
| Pluri Inc. | 34.11 Million USD | -49.809% |
| Prothena Corporation plc | 135.01 Million USD | 62.151% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 78.979% |
| Celularity Inc. | 102.92 Million USD | 50.351% |
| Rallybio Corporation | 9.43 Million USD | -441.575% |
| Cue Biopharma, Inc. | 24.44 Million USD | -109.053% |
| MeiraGTx Holdings plc | 319.99 Million USD | 84.03% |
| Omeros Corporation | 403.25 Million USD | 87.327% |
| Humacyte, Inc. | 114.67 Million USD | 55.437% |
| Immunocore Holdings plc | 228.15 Million USD | 77.602% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -948.267% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | 33.408% |
| Blueprint Medicines Corporation | 918.64 Million USD | 94.437% |
| CalciMedica, Inc. | 4.02 Million USD | -1168.694% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -192.82% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 66.847% |
| Scholar Rock Holding Corporation | 85.81 Million USD | 40.451% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 81.604% |
| Pulmatrix, Inc. | 15.96 Million USD | -220.134% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -223.99% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -107.685% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 79.625% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -0.624% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 95.779% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -60.787% |
| Nutriband Inc. | 1.07 Million USD | -4636.5% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -380.608% |
| Vor Biopharma Inc. | 59.1 Million USD | 13.537% |
| Roivant Sciences Ltd. | 773.95 Million USD | 93.397% |
| Evogene Ltd. | 17.99 Million USD | -184.063% |
| ProKidney Corp. | 29.21 Million USD | -74.914% |
| Applied Therapeutics, Inc. | 71.97 Million USD | 29.003% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -7148.827% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 97.295% |
| CorMedix Inc. | 11.91 Million USD | -328.805% |
| BioLineRx Ltd. | 50.7 Million USD | -0.791% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 65.808% |
| Galectin Therapeutics Inc. | 88.44 Million USD | 42.218% |
| Atai Life Sciences N.V. | 49.16 Million USD | -3.948% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -64.042% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -184.506% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | 58.998% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -803.838% |
| MediciNova, Inc. | 3.89 Million USD | -1213.178% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -179.572% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -3297.261% |
| GeoVax Labs, Inc. | 3.51 Million USD | -1351.839% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 87.136% |
| Biomea Fusion, Inc. | 30.69 Million USD | -66.514% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 98.122% |
| Mereo BioPharma Group plc | 15.96 Million USD | -220.154% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -63.786% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | 12.918% |
| Absci Corporation | 58.3 Million USD | 12.351% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -168.285% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -59.388% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | 30.745% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | 41.585% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -51.327% |
| Allakos Inc. | 74.79 Million USD | 31.674% |
| Imunon, Inc. | 8.53 Million USD | -499.067% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -127.114% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 55.49% |
| BioAtla, Inc. | 48.98 Million USD | -4.322% |
| NLS Pharmaceutics AG | 10.68 Million USD | -378.483% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1738.899% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 60.872% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -259.501% |
| XOMA Corporation | 145.58 Million USD | 64.897% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -51.799% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 25.678% |
| aTyr Pharma, Inc. | 31.59 Million USD | -61.734% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | 17.34% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -13.651% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -5.58% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -1680.592% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -526.414% |
| Akari Therapeutics, Plc | 4.58 Million USD | -1014.812% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -188.178% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 96.902% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -12552.139% |
| UroGen Pharma Ltd. | 243.52 Million USD | 79.015% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 84.084% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1750.513% |
| Orgenesis Inc. | 35.53 Million USD | -43.81% |
| Entera Bio Ltd. | 1.37 Million USD | -3605.801% |
| GH Research PLC | 6.7 Million USD | -662.618% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -651.515% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -171.449% |
| Xencor, Inc. | 283.55 Million USD | 81.978% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -1611.606% |
| Replimune Group, Inc. | 113.21 Million USD | 54.862% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -1260.162% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | 50.639% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -12552.139% |
| Portage Biotech Inc. | 4.45 Million USD | -1048.382% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -3297.261% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -121.705% |
| OncoCyte Corporation | 49.29 Million USD | -3.661% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -1135.325% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -6308.028% |
| Purple Biotech Ltd. | 10 Million USD | -410.775% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -783.218% |
| scPharmaceuticals Inc. | 57.26 Million USD | 10.754% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -312.519% |
| HilleVax, Inc. | 78.9 Million USD | 35.238% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -911.941% |
| Tharimmune, Inc. | 1.81 Million USD | -2715.521% |
| Genprex, Inc. | 3.25 Million USD | -1470.367% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -88.44% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -875.993% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -24707.282% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -14152.764% |
| OKYO Pharma Limited | 7.42 Million USD | -588.641% |
| Savara Inc. | 37.19 Million USD | -37.403% |
| Curis, Inc. | 57.61 Million USD | 11.298% |
| Daré Bioscience, Inc. | 26.32 Million USD | -94.088% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -30.365% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -3438.989% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -145.463% |
| BeiGene, Ltd. | 2.23 Billion USD | 97.712% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -140.035% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 80.525% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -140.213% |
| Erasca, Inc. | 78.61 Million USD | 34.993% |
| bluebird bio, Inc. | 424.62 Million USD | 87.965% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -7698.984% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 97.296% |
| DBV Technologies S.A. | 42.8 Million USD | -19.4% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -7698.984% |
| Moderna, Inc. | 4.57 Billion USD | 98.882% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -630.565% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -2985.93% |
| Molecular Templates, Inc. | 31.17 Million USD | -63.944% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -199.373% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 91.311% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | 58.955% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -86.256% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -40.177% |
| Cogent Biosciences, Inc. | 55.63 Million USD | 8.146% |
| MacroGenics, Inc. | 154.2 Million USD | 66.861% |
| RenovoRx, Inc. | 4.46 Million USD | -1044.268% |
| Adicet Bio, Inc. | 37.12 Million USD | -37.67% |
| Prime Medicine, Inc. | 60.78 Million USD | 15.921% |
| Aditxt, Inc. | 28.53 Million USD | -79.11% |
| Adagene Inc. | 45.16 Million USD | -13.136% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -28180.419% |
| Quantum-Si incorporated | 26.63 Million USD | -91.893% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 92.674% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -1579.673% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | 55.548% |
| SciSparc Ltd. | 1.59 Million USD | -3103.95% |
| Vericel Corporation | 127.7 Million USD | 59.984% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -818.31% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | 40.131% |
| Generation Bio Co. | 171.63 Million USD | 70.225% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -342.45% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -22.165% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 79.777% |
| Invivyd, Inc. | 51.71 Million USD | 1.18% |
| Relay Therapeutics, Inc. | 91.97 Million USD | 44.439% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -685.565% |
| Spero Therapeutics, Inc. | 75.49 Million USD | 32.31% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -4905.191% |
| 2seventy bio, Inc. | 310.12 Million USD | 83.522% |
| ADMA Biologics, Inc. | 193.97 Million USD | 73.655% |
| Clene Inc. | 38.95 Million USD | -31.198% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -41.431% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 80.114% |
| GeoVax Labs, Inc. | 3.51 Million USD | -1351.839% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 73.141% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -319.577% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 74.232% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -319.056% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -6.219% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | 3.289% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 86.183% |
| Evaxion Biotech A/S | 17.61 Million USD | -190.07% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 68.245% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 66.64% |
| Trevena, Inc. | 48.26 Million USD | -5.887% |
| Surrozen, Inc. | 8.14 Million USD | -527.416% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -136.643% |
| Cingulate Inc. | 10.36 Million USD | -393.231% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -1758.291% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -37.035% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -1324.863% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -288.616% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 83.889% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -105.654% |
| Clearmind Medicine Inc. | 3.61 Million USD | -1315.592% |
| Kronos Bio, Inc. | 54.2 Million USD | 5.716% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -8.63% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -124.533% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -154.611% |
| Statera Biopharma, Inc. | 22.67 Million USD | -125.357% |
| ImmunityBio, Inc. | 1.09 Billion USD | 95.313% |
| Korro Bio, Inc. | 51.75 Million USD | 1.254% |
| Kineta, Inc. | 7.22 Million USD | -607.602% |
| BioVie Inc. | 9.7 Million USD | -426.719% |
| Codexis, Inc. | 49.94 Million USD | -2.317% |
| Celularity Inc. | 102.92 Million USD | 50.351% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | 46.904% |
| Celcuity Inc. | 51.45 Million USD | 0.675% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -14704.139% |
| Cibus, Inc. | 206.11 Million USD | 75.207% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -20.313% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -94.02% |
| IN8bio, Inc. | 8.77 Million USD | -482.57% |
| Kodiak Sciences Inc. | 213.59 Million USD | 76.074% |
| Annexon, Inc. | 47.11 Million USD | -8.457% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | 42.928% |
| Assembly Biosciences, Inc. | 96.37 Million USD | 46.973% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -273.314% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.037% |
| Eyenovia, Inc. | 19.78 Million USD | -158.353% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 71.142% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -565.317% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -112.054% |
| Arcellx, Inc. | 339.75 Million USD | 84.959% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -329.509% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 79.188% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -434.383% |
| Moolec Science SA | 13.94 Million USD | -266.452% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -18.426% |
| Geron Corporation | 146.12 Million USD | 65.028% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -1.13% |
| Royalty Pharma plc | 6.29 Billion USD | 99.189% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -28.477% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -17258.002% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -1977.12% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 72.984% |
| Humacyte, Inc. | 114.67 Million USD | 55.437% |
| Structure Therapeutics Inc. | 29.05 Million USD | -75.908% |
| 89bio, Inc. | 59.96 Million USD | 14.776% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -93.111% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -4172.826% |
| Genelux Corporation | 8.42 Million USD | -506.924% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -645.376% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 62.512% |
| Notable Labs, Ltd. | 4.42 Million USD | -1054.348% |
| Liquidia Corporation | 73.13 Million USD | 30.128% |
| Mustang Bio, Inc. | 17.61 Million USD | -190.045% |
| Immunovant, Inc. | 48.95 Million USD | -4.388% |
| Quantum-Si incorporated | 26.63 Million USD | -91.893% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -33.14% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -1546.89% |
| Vera Therapeutics, Inc. | 73.86 Million USD | 30.812% |
| Acasti Pharma Inc. | 11.55 Million USD | -342.182% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -126.042% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -1779.888% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -38.577% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -3649.738% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -738.304% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -105.77% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -120.424% |
| PepGen Inc. | 34.63 Million USD | -47.564% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -320.809% |
| United Therapeutics Corporation | 1.18 Billion USD | 95.677% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -631.715% |
| Solid Biosciences Inc. | 38.45 Million USD | -32.88% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -497.193% |
| Immuneering Corporation | 12 Million USD | -325.562% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -16182.204% |
| Silo Pharma, Inc. | 1.56 Million USD | -3156.482% |
| Belite Bio, Inc | 4.21 Million USD | -1113.56% |
| XOMA Corporation | 145.58 Million USD | 64.897% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -2004.736% |
| Bionomics Limited | 10.15 Million USD | -403.046% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -137.788% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -123.031% |
| uniQure N.V. | 624.01 Million USD | 91.811% |
| Cassava Sciences, Inc. | 14.19 Million USD | -260.007% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -28180.419% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 69.972% |
| Forte Biosciences, Inc. | 3.66 Million USD | -1293.972% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -19511.026% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -657.418% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -565.317% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -193.983% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -383.564% |
| Altimmune, Inc. | 16.54 Million USD | -208.947% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 91.727% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -123.031% |
| Compugen Ltd. | 55.77 Million USD | 8.377% |
| Peak Bio, Inc. | 20.75 Million USD | -146.24% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | 53.737% |
| Benitec Biopharma Inc. | 4.96 Million USD | -929.887% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 67.624% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | 32.02% |
| Zura Bio Limited | 21.29 Million USD | -140.01% |
| PolyPid Ltd. | 17.46 Million USD | -192.552% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | 54.534% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | 32.02% |
| Instil Bio, Inc. | 99.8 Million USD | 48.795% |
| argenx SE | 444.95 Million USD | 88.515% |
| Immunome, Inc. | 28.65 Million USD | -78.32% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -512.966% |
| Verona Pharma plc | 58.84 Million USD | 13.151% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -253.092% |
| Shattuck Labs, Inc. | 14.85 Million USD | -243.92% |
| CervoMed Inc. | 2.59 Million USD | -1868.72% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -948.482% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -301.248% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -385.078% |
| Moolec Science SA | 13.94 Million USD | -266.452% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -2080.624% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | 8.08% |
| AnaptysBio, Inc. | 364.28 Million USD | 85.972% |
| Design Therapeutics, Inc. | 11.95 Million USD | -327.426% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -302.893% |
| NeurAxis, Inc. | 1.91 Million USD | -2571.718% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -31.276% |
| Lumos Pharma, Inc. | 13.33 Million USD | -283.282% |
| Achilles Therapeutics plc | 19.08 Million USD | -167.737% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -253.092% |
| 180 Life Sciences Corp. | 5.38 Million USD | -848.599% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -116.648% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -124.533% |
| Nutriband Inc. | 1.07 Million USD | -4636.5% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -67.014% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -252.167% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 87.265% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -57.371% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -291.621% |
| Palisade Bio, Inc. | 2.73 Million USD | -1765.754% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -872.835% |
| Beam Therapeutics Inc. | 478.38 Million USD | 89.318% |
| Neurogene Inc. | 36.54 Million USD | -39.821% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 87.158% |
| AEON Biopharma, Inc. | 159.88 Million USD | 68.038% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -7.247% |
| Sesen Bio, Inc. | 30.98 Million USD | -64.934% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -96.845% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -572.212% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 73.892% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 73.392% |
| Athira Pharma, Inc. | 30.05 Million USD | -70.02% |
| Vaccinex, Inc. | 5.94 Million USD | -760.03% |
| HCW Biologics Inc. | 15.05 Million USD | -239.511% |
| XOMA Corporation | 145.58 Million USD | 64.897% |
| Nektar Therapeutics | 267.04 Million USD | 80.864% |
| Arvinas, Inc. | 644.6 Million USD | 92.072% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -188.178% |
| Merus N.V. | 102.15 Million USD | 49.973% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 65.082% |
| Quince Therapeutics, Inc. | 95.12 Million USD | 46.275% |
| Rezolute, Inc. | 11.73 Million USD | -335.512% |
| Clene Inc. | 38.95 Million USD | -31.198% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -1694.738% |
| BeyondSpring Inc. | 48.26 Million USD | -5.871% |
| Synlogic, Inc. | 32.89 Million USD | -55.352% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -249.709% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -3027.479% |
| Peak Bio, Inc. | 20.75 Million USD | -146.24% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | 19.471% |
| Krystal Biotech, Inc. | 39.71 Million USD | -28.678% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 86.432% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | 48.676% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -11709.552% |
| MannKind Corporation | 721.36 Million USD | 92.916% |
| Ikena Oncology, Inc. | 22.33 Million USD | -128.802% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -2349.808% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | 50.187% |
| Gossamer Bio, Inc. | 249.14 Million USD | 79.489% |
| CohBar, Inc. | 1.03 Million USD | -4843.994% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -378.09% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -168.285% |
| Legend Biotech Corporation | 589.93 Million USD | 91.337% |
| Mural Oncology plc | 37.92 Million USD | -34.737% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 61.471% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -2126.388% |
| Disc Medicine, Inc. | 22.87 Million USD | -123.401% |
| Champions Oncology, Inc. | 28.03 Million USD | -82.283% |
| REGENXBIO Inc. | 262.22 Million USD | 80.512% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -1421.216% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -307.715% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -280.468% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -140.995% |
| Vaxart, Inc. | 34.02 Million USD | -50.193% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -150.637% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -79.108% |
| Cellectis S.A. | 249.57 Million USD | 79.524% |
| Longeveron Inc. | 5.33 Million USD | -857.523% |
| Repare Therapeutics Inc. | 41.81 Million USD | -22.2% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 97.875% |
| Inozyme Pharma, Inc. | 60.36 Million USD | 15.348% |
| Revolution Medicines, Inc. | 262.39 Million USD | 80.525% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -2325.392% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -492.43% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -333.04% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -263.904% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -2275.779% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.008% |
| Denali Therapeutics Inc. | 122.96 Million USD | 58.44% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -818.31% |
| Veru Inc. | 32.81 Million USD | -55.741% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -643.966% |
| Cingulate Inc. | 10.36 Million USD | -393.231% |
| Passage Bio, Inc. | 39.26 Million USD | -30.159% |
| Context Therapeutics Inc. | 4.19 Million USD | -1119.143% |
| Exicure, Inc. | 8.54 Million USD | -497.766% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -73.184% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -387.345% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -131.854% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 68.646% |
| Nuvalent, Inc. | 31.82 Million USD | -60.585% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -703.301% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | 18.912% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -183.906% |
| OmniAb, Inc. | 87.4 Million USD | 41.53% |
| Anew Medical, Inc. | 8.24 Million USD | -520.047% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -33.466% |
| Lipocine Inc. | 2.63 Million USD | -1841.877% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -94.515% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -27.084% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -91.815% |
| G1 Therapeutics, Inc. | 86.15 Million USD | 40.684% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -846.177% |
| Sage Therapeutics, Inc. | 82.74 Million USD | 38.242% |
| Ocugen, Inc. | 23.98 Million USD | -113.08% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -10.119% |
| Q32 Bio Inc. | 233.12 Million USD | 78.079% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -463.677% |
| Alumis Inc. Common Stock | 53.5 Million USD | 4.484% |
| Equillium, Inc. | 27.95 Million USD | -82.791% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 75.264% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -808.229% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -733.251% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 67.518% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 26.4% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -412.352% |
| Dominari Holdings Inc. | 4.63 Million USD | -1002.546% |
| Edesa Biotech, Inc. | 1.84 Million USD | -2674.868% |
| vTv Therapeutics Inc. | 29.56 Million USD | -72.838% |
| Bio-Techne Corporation | 744.34 Million USD | 93.134% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 59.474% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 85.164% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -25.947% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -76.479% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | 44.67% |
| Nkarta, Inc. | 105.6 Million USD | 51.607% |
| BioCardia, Inc. | 4.59 Million USD | -1013.355% |
| Iterum Therapeutics plc | 32.66 Million USD | -56.46% |